futurhealth tirzepatide yourfuturhealth update! #ad #tirzepatide #glp1 #tirzepatideweightloss # FuturHealth: GLP-1s + Meals =

For most patients, the warmth stabilizes within weeks and becomes background noise noticeable but not disruptive

Neuron 25 FerreiraG

The safety profile was consistent with GLP-1 receptor agonists, primarily featuring transient, mild-to-moderate gastrointestinal adverse events (e.g., nausea, 55%), with low discontinuation rates (6-8.4%)

In preclinical publications, retatrutide / LY3437943 was described as a single peptide exhibiting agonist activity towards three receptors: the glucagon receptor GCGR, the glucose-dependent insulinotropic peptide receptor GIPR and the glucagon-like peptide-1 receptor GLP-1R

Both conditions involve damage to the retina or optic nerve and can cause sudden, often lasting vision loss